Interventions of interest:

  • Erenumab (Aimovig®, Amgen/Novartis)
  • Fremanezumab (Ajovy®, Teva)
  • Galcanezumab (Emgality®, Eli Lilly)

Migraine is a common, recurrent headache disorder and is among the top ten causes of years lived with disability in the US. Someone experiencing a migraine episode may feel moderate-to-severe pain and other symptoms (e.g., nausea, vomiting, or sensitivity to light or to sound), have a reduced ability to function, or require bed rest. Despite its high prevalence and impairment, migraine is often not recognized or effectively treated.

For questions or additional information, please contact info@icer.org.

View the Key Stakeholders List.


Final Documents

Below you will find the final documents from the assessment review process:

Final Evidence Report & Meeting SummaryDownload
Report-at-a-GlanceDownload
Response to Comments on Draft Evidence ReportDownload

ICER’s Chief Medical Officer David Rind, MD, MSc stated:

“CGRP inhibitors appear to offer modest improvements in outcomes for patients with chronic migraine and frequent episodic migraine. For individuals for whom prior preventive therapies have not been effective or tolerated, the price of erenumab after expected discounts seems to align with those added benefits for patients. However, as with any new class of medication only tested in trials of several months’ duration, concerns remain about unanticipated harms. Additionally, migraine is common, and there may be concerns about affordability and access. While the therapies are cost-effective in the long-term, CGRP inhibitors could potentially have a significant impact on short-term health budgets. During our public meeting in June, we will convene stakeholders from all perspectives to identify opportunities to ensure access for those patients for whom these therapies are appropriate, while balancing the need to maintain affordability.”